The Latest

  • An illustration of two neurons, colored blue and purple
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A

    MapLight CEO on what investors missed in the biotech’s schizophrenia data

    Though positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Christopher Kroeger sees MapLight's drug as competitive based on the "totality of data."

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Apnimed raised $192 million in the biopharmaceutical sector’s 15th IPO this year, while a trio of other drugmakers — Braveheart Bio, Attovia Therapeutics and Vogenx — set terms for coming offerings.

    Updated July 31, 2026
  • Johnson & Johnson's pharmaceutical office in Madrid, Spain.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B

    The deal with the buzzy Flagship Pioneering-backed startup makes J&J the latest large drugmaker to bet that the technology might be able to treat autoimmune conditions.

  • An illustration of necrotic muscle fiber in Duchenne muscular dystrophy.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Capricor Duchenne cell therapy voted down by FDA panel

    At a contentious meeting with possible implications for other rare disease drugmakers, outside experts ultimately determined that Capricor didn't prove deramiocel's benefits in Duchenne-related cardiomyopathy.

    FDA
  • A modern architectural design building featuring a red-brick façade with large glass windows displays a prominent sign of the Food and Drug Administration.
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Trump administration

    5 FDA decisions to watch in the third quarter of 2026

    A group of coming decisions could provide important insights into how flexible the agency is willing to be under new leadership.

    FDA
  • Hims & Hers Super Bowl ad header
    Image attribution tooltip
    Courtesy of Hims & Hers
    Image attribution tooltip

    FTC sues Hims & Hers over alleged privacy violations, deceptive billing practices

    Regulators say the telehealth company illegally shared patients’ health data with advertisers and misled its customers. Hims & Hers hit back, calling the claims “baseless.”

  • A street sign for Wall Street in front of the facade of the New York Stock Exchange.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Caldera, Vidya add to recent flurry of biotech mergers

    The startups are part of a surge of young companies equipped with advanced drug prospects and quickly pivoting to the public markets.

  • A person in a lab coat is seen through a well-lit, organized laboratory environment featuring shelves stocked with additional lab supplies and instruments.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    The FDA was all in on AI. Will that change?

    High-level turnover has introduced uncertainty about how quickly the FDA’s agency-wide AI strategy will move forward.

    FDA
  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GSK prepares for patent cliff with $2.5B cost-cutting plan

    The pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss of patents important to its HIV drug franchise.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data

    Replimune shares plummeted 40% on concerns FDA scientists are still skeptical of its melanoma drug. Elsewhere, investors had a muted reaction to a first-of-its-kind study result.

  • Vertex bldg
    Image attribution tooltip
    Permission granted by Vertex Pharmaceuticals
    Image attribution tooltip

    AbCellera, Vertex partner on next-gen T-cell engagers

    The deal adds to a growing streak of partnerships involving new types of T cell engagers and gives Vertex another chance to broaden a business still reliant on cystic fibrosis medicines.

  • A red magnifying glass sits on top of cash.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    An eye drug biotech banks $118M and stocks its executive suite

    Claris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for a blinding condition called limbal stem cell deficiency.

  • A Sarepta logo is displayed on a building in Cambridge, Massachusetts on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO

    Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company facing emerging competition and declining sales for its prized gene therapy Elevidys.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    FDA scientists question Capricor data; Legend CEO steps down

    Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipeline trouble.

  • Abstract financial graph with up trend line on neon light colour background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Brain drug revival

    MapLight dives despite positive data for schizophrenia drug

    Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with Bristol Myers' Cobenfy.

  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip
    Trump administration

    FDA panel endorses broader use of certain peptides

    In a victory for Robert F. Kennedy Jr.’s “MAHA” agenda, panelists narrowly recommended broader use of six of the seven peptides up for consideration despite a lack of substantive evidence supporting their benefits and safety.

    Updated July 26, 2026
    FDA
  • Pills lie on top of hundred dollar bills.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug

    The deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among multiple developers.

  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi halts development of troubled immune drug in eczema

    The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future blockbuster. One analyst expects Sanofi to now pursue “strategic action” to boost its pipeline.

  • Close up of Wall Street sign, with tall buildings in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Scribe secures $129M in a rare gene editing IPO

    The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other biotechs that have gone public in 2026.

  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly, with new data, to seek FDA approval of obesity drug retatrutide

    The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.

    FDA
  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is accelerating. Track the deals that are happening here.

    Argenx is paying $2.2 billion to acquire Forte Biosciences, the developer of a CD122-targeting antibody drug that’s shown early promise against multiple immunological conditions.

    Updated July 27, 2026
  • Vertex bldg
    Image attribution tooltip
    Permission granted by Vertex Pharmaceuticals
    Image attribution tooltip

    Vertex was sole bidder in high-premium Crinetics acquisition

    Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in what’s poised to be its largest-ever transaction.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma

    Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.

  • A photo of a building showing a GSK sign in London.
    Image attribution tooltip
    Courtesy of GSK
    Image attribution tooltip

    GSK lung cancer drug gets speedy approval following $10.6B deal

    The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.

  • An injection pen containing the drug semaglutide lies on a white plate.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs

    The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that its campaign is “truthful.”